Danske Bank A S Acquires New Position in Zoetis Inc. $ZTS

Danske Bank A S bought a new position in Zoetis Inc. (NYSE:ZTS) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 396,859 shares of the company’s stock, valued at approximately $58,068,000. Danske Bank A S owned about 0.09% of Zoetis as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of ZTS. CIBC Asset Management Inc increased its position in Zoetis by 4.3% in the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after buying an additional 10,434 shares during the period. Mitsubishi UFJ Trust & Banking Corp lifted its stake in Zoetis by 6.5% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after buying an additional 18,040 shares during the last quarter. Ninety One UK Ltd boosted its holdings in shares of Zoetis by 19.6% during the third quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after acquiring an additional 183,686 shares during the period. Quilter Plc boosted its holdings in shares of Zoetis by 10.2% during the third quarter. Quilter Plc now owns 438,959 shares of the company’s stock valued at $64,228,000 after acquiring an additional 40,615 shares during the period. Finally, Swedbank AB grew its position in shares of Zoetis by 60.4% during the third quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock worth $356,565,000 after acquiring an additional 917,598 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently weighed in on ZTS shares. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Bank of America raised their price target on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. UBS Group set a $136.00 price target on Zoetis in a report on Thursday, January 29th. Finally, Morgan Stanley set a $160.00 price objective on Zoetis in a research report on Thursday, December 18th. Six equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Price Performance

Shares of NYSE ZTS opened at $117.42 on Thursday. The stock has a market cap of $49.57 billion, a P/E ratio of 19.50, a P/E/G ratio of 1.86 and a beta of 0.95. The firm’s 50-day simple moving average is $124.80 and its 200 day simple moving average is $130.99. Zoetis Inc. has a fifty-two week low of $114.47 and a fifty-two week high of $172.23. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.